First Major Deployment at Formula One United States Grand Prix Successfully Identified COVID-19 Infected Staff Prior to Event Entry
Toronto, ON – November 3, 2021 – Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”), an emerging provider of rapid health screening solutions powered by a proprietary artificial intelligence (AI), today announced the launch of the ThuraPass Safe Entry Program in partnership with Uptown Sports Marketing and Connectus Global, providing COVID-19 risk mitigation for attendees and staff within the sports and entertainment industry – leveraging Predictmedix’s proven Safe Entry Station screening technology.
The ThuraPass Safe Entry Program premiered October 1, 2021 at the 2021 Red Bull Moto Grand Prix of the Americas at the Circuit of the Americas in Austin, Texas. The premier was well received and rolled out for its first major deployment at the 2021 Formula One United States Grand Prix in Austin, Texas – marking the highest attended Formula One weekend of all-time, with over 400,000 attendees at the Circuit of the Americas. As part of the program, Predictmedix Safe Entry Stations were set up at indoor hospitality entry points area. Additionally, all catering and hospitality staff were screened before entering the COTA campus.
Upon arrival, guests holding passes to enclosed hospitality areas and suites were asked to pass through the Safe Entry Station to rapidly identify multiple symptoms associated with COVID-19. Average screening time was approximately three seconds, enabling a significant volume of screening in a short period of time.
While the overwhelming majority of fans and staff who were screened by the Predictmedix Safe Entry Stations passed through with no issue, the technology did flag several members of the catering staff who were turned away from the event and sent home for recovery.
“The ThuraPass COVID-19 screening system gives peace of mind to fans entering enclosed spaces, ensuring that venue operations staff are not currently showing signs of infection,” said Michael Kirschner, Co-Founder at Uptown Sports Marketing, a Predictmedix partner. “It is the most efficient and cost-effective way to mitigate risk and provide a safe event.
“With cold weather coming and more than half the country going indoors again, the ThuraPass Safe Entry Program is a way for sports operations groups and venues to add an extra layer of risk mitigation to ensure that everyone is screened when entering a facility,” concluded Kirschner.
About Thurapass Program
For more information about the ThuraPass program contact Uptown Sports Marketing at firstname.lastname@example.org
About Predictmedix Inc.
Predictmedix (CSE: PMED) (OTCQB: PMEDF) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company’s Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, or various mental illnesses. Predictmedix’s proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.
Caution Regarding Forward-Looking Information:
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEA
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.